Quanterix Corporation (QTRX)

Over the past six months, Quanterix Corp. (QTRX) stock has experienced significant downward pressure. The stock price decreased by 32.93% in the past month and 35.38% over the last 12 months. As of April 8, 2026, the share price was $3.50, a decline of 27.98% from April 8, 2025. Key events impacting the stock price include persistent losses and underwhelming sales momentum, the Akoya Biosciences acquisition, 2025 financial results showing a net loss of $107.2 million, and 2026 guidance signaling flat revenues. Everett Cunningham was appointed CEO early in 2026. In January 2026, Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its multi-analyte algorithmic blood test for Alzheimer's disease detection.

Direct information regarding the seasonality of demand for Quanterix Corp.'s products and services was not explicitly found in the provided search results. However, an analysis of QTRX's historical stock price data suggests some seasonality in stock returns. November has the highest probability of positive returns at 75.00%, while April has a 33.33% probability of a positive return. March has the lowest probability of positive returns at 22.22%.

Quanterix Corporation is a life sciences company focused on precision health through ultra-sensitive biomarker detection. Its core mission is to enable researchers to closely examine the continuum from health to disease. The company operates in the Healthcare sector, specifically in the Healthcare Equipment & Supplies industry, and is also categorized under Technology and Scientific & Technical Instruments. Quanterix's major products and services revolve around its proprietary Simoa technology, which allows for the detection of protein biomarkers at ultra-low concentrations. Key offerings include instruments like the HD-X, SR-X, and SP-X, assay kits for enzyme-based immunoassays, contract research and clinical laboratory testing services through its Accelerator Laboratory, and spatial biology solutions following its acquisition of Akoya Biosciences. Quanterix primarily focuses its operations in therapeutic areas such as neurology, oncology, immunology, and inflammation, selling its products to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies.

Quanterix Corporation has a global geographic footprint, operating in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides direct sales and service to customers in North America and several European countries, with its products and services also available globally through distributor partners. Quanterix is headquartered in Billerica, Massachusetts, United States.

Quanterix has established itself as a trusted partner to the scientific community for nearly two decades, with approximately 6,000 peer-reviewed publications featuring its Simoa technology. The company is recognized for its role in revolutionizing precision health through digital protein detection and its focus on ultra-sensitive biomarker detection to advance disease research, diagnostics, and drug development. Investor sentiment is extremely cautious due to financial underperformance and missed promises regarding profitability and revenue targets.

Institutional investors are the dominant force in Quanterix's ownership structure, holding a significant majority of the stock. As of the second quarter of 2025, institutional and hedge fund ownership accounted for 86.48% of the company's stock. Major institutional shareholders include Ameriprise Financial Inc., Portolan Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Insider ownership was reported at 6.59% as of August 4, 2025, and about 7.6% as of November 16, 2025. Individual investors also hold stakes in the company.